C. D. N. Toseland

Peroxisome Proliferator-Activated Receptor-γ Agonist, Rosiglitazone, Protects Against Nephropathy and Pancreatic Islet Abnormalities in Zucker Fatty Rats

Robin E. Buckingham, Kamal Albarazanji, C. D. N. Toseland et al. · Diabetes · 1998 · 205 citations

Hypertension, Zucker Rats, Insulin Signaling +24

Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat

Stephen A. Smith, Carolyn A. Lister, C. D. N. Toseland et al. · Diabetes Obesity and Metabolism · 2000 · 88 citations

Comparison of adipose tissue changes following administration of rosiglitazone in the dog and rat

C. D. N. Toseland, Sue Ann Campbell, Ian Francis et al. · Diabetes Obesity and Metabolism · 2001 · 44 citations

Potential benefit of inhibitors of advanced glycation end products in the progression of type II diabetes: A study with aminoguanidine in C57/BLKsJ diabetic mice

Valerie Piercy, C. D. N. Toseland, Nicholas C. Turner · Metabolism · 1998 · 27 citations

Biochemistry, Medicine, Insulin Management +9

Antiinflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA)

Richard Melarange, Clive Gentry, Peter R. Blower et al. · Digestive Diseases and Sciences · 1992 · 26 citations

Medicinal Chemistry, 6-Methoxy-2-naphthylacetic Acid, Anti-inflammatory +8